2023
Science4Pandemics (S4P) is an EU-funded project that aims to educate young people on how to prevent future pandemics through a game-based learning approach.
S4P needs your support!
S4P is dedicated to young people, and they need your help to reach them! The video game, the webinars, the questionnaires: have a look below at what S4P is working on and help them reach thier audience by sharing this news with your colleagues,
2022
A large study on the effectiveness of the Pfizer-BioNTech’s Covid-19 vaccine in children aged 5-11 was published in The New England Journal of Medicine.
The study was conducted at Israel’s largest healthcare organization, Clalit Health Services, in collaboration with researchers from the University of Padua, Harvard University and University College London.
This is one of the first large observational studies that uses Real-World Data evaluate the effectiveness of the Pfizer-BioNTech BNT162b2 (Comirnaty) vaccine in children aged 5-11 against the Omicron variant.
2022
Padua, 30 June 2022 – A large study on the effectiveness of the Pfizer Covid-19 vaccine in children aged 5-11 was published in The New England Journal of Medicine.
The study was conducted at Israel’s largest healthcare organization, Clalit Health Services, in collaboration with researchers from the University of Padua, Harvard University and University College London.
2022
Funded by the Horizon Europe programme, RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the different variants of COVID-19 using a recombinant protein.
“RBD Dimer recombinant protein vaccine against SARSCoV2” (RBDCOV) is a new Horizon Europe project led by the biotech pharmaceutical company HIPRA.
2021
Johnson & Johnson plans to test its coronavirus vaccine in infants and even in newborns, as well as in pregnant women and in people who have compromised immune systems.
The bold plan for expanded clinical trials met with the approval of Dr. Ofer Levy, director of the Precision Vaccines Program at Harvard’s Boston Children’s Hospital and a member of the Food and Drug Administration advisory committee that reviewed the company’s vaccine data.
2021
In December 2020 Penta held its annual Scientific Meeting. Despite the unusual get together due to COVID-19, we shared great science together. Among the experts invited was Timo Vesikari, a vaccine specialist who provided an insightful overview of the current scenario around COVID-19 vaccine development. He agreed to an interview with us and shed some light on our understanding of COVID-19 vaccines and how they impact children.